Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 25, 2011

View Archived Issues

Serum KL-6 level is a biomarker of prognosis in diffuse alveolar hemorrhage syndrome

Genmab provides pipeline and technology update

Interim phase II data disclosed on nimotuzumab plus irinotecan in gastric cancer

StronBone Sr-substituted bioactive glass implants show promise in bone grafting

Phase I data reported on recombinant angiotensin-converting enzyme 2

Flex-590 confers chondroprotection in a model of osteoarthritis

AMG-369 reduces severity of experimental autoimmune encephalomyelitis

AstraZeneca responds to FDA complete response letter for Brilinta

CHMP issues positive opinion on Eisai's Halaven for metastatic breast cancer

Cytori Therapeutics' ADVANCE trial of ADRCs is cleared to begin in the Netherlands

New blockers of cyclic nucleotide-regulated HCN1 channel claimed

PGxHealth presents new adenosine A2A receptor agonists

Novartis receives Swiss and Austrian approval for Gilenya in relapsing-remitting MS

CHMP recommends European marketing authorization for Trobalt

R-Tech Ueno completes phase IIa RK-023 trial in androgenetic alopecia

CHMP recommends new indications of INOmax

New melanin-concentrating hormone MCH1 receptor antagonists claimed

FDA grants priority review for Optimer Pharma's fidaxomicin NDA

Enrollment complete in pivotal phase III trial of delayed-release cysteamine

Novel PI3K inhibitors described at Novartis

FDA approves Viibryd for major depressive disorder

Otuska submits application to extend indication for Abilify in Japan

FDA recommends approval of Bayer's gadobutrol injection

Eisai decides against submitting marketing applications for eritoran for severe sepsis

Eisai set to submit U.S. and E.U. marketing authorization applications for perampanel

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...